Please be advised that procedures connected with admission of Bioceltix S.A. shares to stock exchange trading are currently being finalized. ...Read full
Łukasz Bzdzion, President of the Management Board, participated in the XXX Economic Forum in Karpacz on behalf of Bioceltix. The second day of ...Read full
At Bioceltix, we develop innovative MSC-based biopharmaceuticals for use in companion animals. We target markets with high demand for effective pharmaceuticals.
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets using drugs with stem cells.